ArticlePeerJ2017
Meta-analysis of biomarkers for severe dengue infections.
Article in PeerJ, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 4 syntheses or guidelines pooled it, 51 citations in OpenAlex.
- Risk and predictive factors for severe dengue infection: A systematic review and meta-analysis.PloS one · 2022Pooled it
- Clinical predictors of severe dengue: a systematic review and meta-analysis.Infectious diseases of poverty · 2021Pooled it
- Predictive markers for the early prognosis of dengue severity: A systematic review and meta-analysis.PLoS neglected tropical diseases · 2021Pooled it
- Risk predictors of progression to severe disease during the febrile phase of dengue: a systematic review and meta-analysis.The Lancet. Infectious diseases · 2021Pooled it
- A multicenter prospective observational multi-omics study protocol to identify biomarkers for severe dengue: COMBAT study clinical protocol.BMC infectious diseases · 2026Observational
- Beyond Hemostasis: Platelet Biomarkers and Vascular-Immune Crosstalk in Dengue.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Review
- Article
- Exploiting host kinases to combat dengue virus infection and disease.Antiviral research · 2025Review
- Pathogenesis and clinical management of arboviral diseases.World journal of virology · 2025Review
- Dengue: epidemiology, diagnosis methods, treatment options, and prevention strategies.Archives of virology · 2025Review
- Ultrasound evaluation of gallbladder wall thickness for predicting severe dengue: a systematic review and meta-analysis.The ultrasound journal · 2025Review
- Temporal cytokine storm dynamics in dengue infection predicts severity.Virus research · 2024Article
- Markers of prolonged hospitalisation in severe dengue.PLoS neglected tropical diseases · 2024Article
- DENV-specific IgA contributes protective and non-pathologic function during antibody-dependent enhancement of DENV infection.PLoS pathogens · 2023Article
- The Role of Growth Factors in the Pathogenesis of Dengue: A Scoping Review.Pathogens (Basel, Switzerland) · 2022Article
- The association of ultrasound assessment of gallbladder wall thickness with dengue fever severity.The ultrasound journal · 2022Article
- Immunophenotyping and Transcriptional Profiling of Human Plasmablasts in Dengue.Journal of virology · 2021Article
- Dengue and the Lectin Pathway of the Complement System.Viruses · 2021Review
- Article
- Current Understanding of the Pathogenesis of Dengue Virus Infection.Current microbiology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDengue viral infection is an acute infection that has the potential to have severe complications as its major sequela. Currently, there is no routine laboratory biomarker with which to predict the severity of dengue infection or monitor the effectiveness of standard management. Hence, this meta-analysis compared biomarker levels between dengue fever (DF) and severe dengue infections (SDI) to identify potential biomarkers for SDI.
methodsData concerning levels of cytokines, chemokines, and other potential biomarkers of DF, dengue hemorrhagic fever, dengue shock syndrome, and severe dengue were obtained for patients of all ages and populations using the Scopus, PubMed, and Ovid search engines. The keywords "(IL1* or IL-1*) AND (dengue*)" were used and the same process was repeated for other potential biomarkers, according to Medical Subject Headings terms suggested by PubMed and Ovid. Meta-analysis of the mean difference in plasma or serum level of biomarkers between DF and SDI patients was performed, separated by different periods of time (days) since fever onset. Subgroup analyses comparing biomarker levels of healthy plasma and sera controls, biomarker levels of primary and secondary infection samples were also performed, as well as analyses of different levels of severity and biomarker levels upon infection by different dengue serotypes.
resultsFifty-six studies of 53 biomarkers from 3,739 dengue cases (2,021 DF and 1,728 SDI) were included in this meta-analysis. Results showed that RANTES, IL-7, IL-8, IL-10, IL-18, TGF-b, and VEGFR2 levels were significantly different between DF and SDI. IL-8, IL-10, and IL-18 levels increased during SDI (95% CI, 18.1-253.2 pg/mL, 3-13 studies, DISCUSSION: This meta-analysis suggests that IL-7, IL-8, IL-10, TGF-b, and VEGFR2 may be used as potential early laboratory biomarkers in the diagnosis of SDI. This can be used to predict the severity of dengue infection and to monitor the effectiveness of treatment. Nevertheless, methodological and reporting limitations must be overcome in future research to minimize variables that affect the results and to confirm the findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.